Sugi Predict

Sugi Predict / Compounds / SCHEMBL20583565

SCHEMBL20583565

SCHEMBL20583565

O=C(NNC(C1CCOCC1)C(F)(F)F)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 1/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ CTDSP1 Q9GZU7 1/20 0.40
▸ POLB P06746 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ P2RX7 Q99572 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ IDH1 O75874 1/20 0.37
▸ P2RX1 P51575 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20583499 0.92 RAB9A (0.46) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL20583592 0.88 RAB9A (0.44) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL20583729 0.86 RAB9A (0.46) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL8553015 0.72 SMN1; SMN2 (0.47) CCR2NPC1RAB9ACTDSP1POLB
SCHEMBL8173186 0.72 POLB (0.50) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL30047341 0.71 NAMPT (0.50) CCR2RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL26110369 0.69 SMN1; SMN2 (0.46) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL20583509 0.69 SMN1; SMN2 (0.46) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL8167085 0.69 EPHX2 (0.51) NPC1RAB9ACTDSP1POLBSMN1; SMN2
SCHEMBL18988741 0.68 CYP3A4 (0.35) CCR2TSHRP2RX7HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 — — US disclosed
US-12220401-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2025-02-11 — — US disclosed
US-11826351-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2023-11-28 — — US disclosed
US-20230372298-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2023-11-23 — — US disclosed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 — — CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 — — CN disclosed
CN-114621146-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-14 — — CN disclosed
CN-114605327-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-10 — — CN disclosed
CN-114591242-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-07 — — CN disclosed
CN-114573510-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-03 — — CN disclosed
EP-3782994-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS Loxo Oncology, Inc. (US) 2021-02-24 — — EP disclosed
US-10918622-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2021-02-16 — — US disclosed
EP-3390395-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2020-09-09 — — EP disclosed
US-20200276162-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2020-09-03 — — US disclosed
US-10695323-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2020-06-30 — — US disclosed
US-10464905-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2019-11-05 — — US disclosed
US-10342780-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2019-07-09 — — US disclosed
US-20190135762-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2019-05-09 — — US disclosed
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2019-01-03 — — US disclosed
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2018-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12220401-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-20190135762-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-10918622-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-20200276162-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-11826351-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-10695323-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-20230372298-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-10464905-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-10342780-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CCR2 1418/4885NPC1 3295/4885RAB9A 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback